On May 6, 2026, a significant cluster of insider activity was observed at Hemab Therapeutics Holdings, Inc. (COAG). Twenty-four insiders, including directors and 10% owners associated with RA Capital, collectively purchased approximately $309.71 million worth of company stock.
The transactions occurred at various price points, with notable purchases including over 2.5 million shares each for Capital Healthcare Fund LP, Capital Management L.P., Peter Kolchinsky, Rajeev M. Shah, Capital Nexus Fund II L.P., and Capital Nexus Fund IV L.P. at $18.00 per share, totaling $45.74 million for each entity.
This coordinated buying by multiple high-ranking individuals within the company is often interpreted as a strong bullish signal, suggesting confidence in Hemab Therapeutics' future prospects.